Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
CAPS Rating:
A biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease.
The Official Website of the Long-Term Investor
A biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Big diabetes market for there main drug LX4211. It's the only drug that inhibits SLGT1 and SLGT2 which can treat both type 1 diabetes and type 2. No one has taken notice of this stock yet. They are also going to be partnering in the next few months with a large biopharma company to get LX4211 rolling.